Savella May Reduce Pain, Alter Brain Activity in Fibromyalgia Patients, Study Suggests

Savella May Reduce Pain, Alter Brain Activity in Fibromyalgia Patients, Study Suggests
Treatment with Savella (milnacipran, by Allergan) may reduce pain sensitivity and increase activity in pain-related brain regions of patients with fibromyalgia. The study, “Using fMRI to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia,” appeared in the Scandinavian Journal of Pain. Savella, although not used to treat depression, acts like an antidepressant. It is one of two antidepressant medications approved by the U.S. Food and Drug Administration to treat fibromyalgia. Savella, a serotonin-noradrenalin reuptake inhibitor (SNRI), increases the levels of the neutrotransmitters noradrenaline and serotonin in the brain and spinal cord, but the exact mechanisms by which Savella eases fibromyalgia symptoms are still unknown. Studies have demonstrated that pain regulation is impaired in the central nervous system of fibromyalgia patients. Using functional magnetic resonance imaging (fMRI), patients showed higher pain intensities in response to pressure and associated increases in brain activity in pain-related brain areas compared to healthy individuals (controls). Other studies
Subscribe or to access all post and page content.